Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for GTBP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 3.569M
March 31, 2026 7.58M
December 31, 2025 5.787M
September 30, 2025 3.00M
June 30, 2025 -23.92M
March 31, 2025 -0.98M
December 31, 2024 -1.67M
September 30, 2024 2.097M
June 30, 2024 5.508M
March 31, 2024 5.312M
December 31, 2023 7.476M
September 30, 2023 10.00M
June 30, 2023 11.76M
March 31, 2023 13.05M
December 31, 2022 11.73M
September 30, 2022 15.95M
June 30, 2022 15.44M
March 31, 2022 17.79M
December 31, 2021 21.91M
September 30, 2021 32.04M
June 30, 2021 36.46M
March 31, 2021 24.19M
December 31, 2020 -29.26M
September 30, 2020 -29.61M
June 30, 2020 -27.33M
Date Value
March 31, 2020 -20.69M
December 31, 2019 -19.14M
September 30, 2019 -18.12M
June 30, 2019 9.145M
March 31, 2019 10.18M
December 31, 2018 11.54M
September 30, 2018 13.48M
June 30, 2018 246.23M
March 31, 2018 252.43M
December 31, 2017 251.86M
September 30, 2017 253.89M
June 30, 2017 -19.92M
March 31, 2017 -17.94M
December 31, 2016 -18.76M
September 30, 2016 -17.04M
June 30, 2016 -15.66M
March 31, 2016 -20.05M
December 31, 2015 -50.40M
September 30, 2015 -24.38M
June 30, 2015 -22.73M
March 31, 2015 -49.76M
December 31, 2014 -29.40M
September 30, 2014 -10.75M
June 30, 2014 -6.814M
March 31, 2014 -6.552M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics